despit
advanc
immunosuppress
surgic
techniqu
donor
recipi
screen
increas
life
expect
renal
transplant
recipi
infecti
complic
remain
signifi
cant
caus
morbid
mortal
among
renal
transplant
recipi
recent
analysi
us
renal
data
system
databas
found
patient
receiv
tranplant
hospit
discharg
diagnosi
includ
infect
fi
rst
year
transplant
unfortun
incid
infect
posttranspl
period
seem
increas
total
infectionrel
hospit
discharg
diagnos
increas
year
sinc
clinician
challeng
lie
prevent
earli
diagnosi
treatment
infect
popul
hamper
lack
standard
diagnost
test
mani
pathogen
often
atyp
present
infecti
diseas
immunocompromis
patient
addit
mani
commonli
use
antimicrobi
signifi
cant
drug
interact
immunosuppress
medic
put
patient
risk
allograft
reject
toxic
advers
effect
drugdrug
interact
import
list
tabl
howev
clinician
alway
check
drug
interact
prescrib
antimicrobi
prefer
input
clinic
pharmacist
avail
although
list
pathogen
may
caus
diseas
transplant
recipi
continu
increas
broad
class
infect
contain
sever
typic
organ
practition
familiar
one
help
method
think
infect
transplant
patient
consid
much
time
elaps
sinc
transplant
occur
infect
tend
manifest
certain
time
window
surgeri
fi
nding
summar
chart
form
fishman
fig
fi
rst
month
posttranspl
nosocomi
infect
tend
predomin
includ
wound
catheterrel
bacteri
fungal
infect
fl
are
prior
latent
allografttransmit
virus
prophylaxi
given
ie
herp
simplex
viru
hsv
hepat
b
hepat
c
follow
month
viral
infect
predomin
includ
reactiv
primari
infect
varicellazost
viru
vzv
epsteinbarr
viru
ebv
cytomegaloviru
cmv
although
patient
receiv
antivir
prophylaxi
diseas
may
delay
prophylaxi
discontinu
patient
also
increasingli
suscept
communityacquir
respiratori
virus
environment
fungi
parasit
begin
travel
congreg
other
outsid
healthcar
set
month
risk
opportunist
infect
declin
period
maximum
immunosuppress
pass
communityacquir
pathogen
posttranspl
lymphoprolif
diseas
ptld
tend
common
use
vaccin
transplant
select
prophylaxi
regimen
transplant
along
good
infect
control
practic
common
sens
guidelin
recipi
minim
highrisk
exposur
discharg
greatli
reduc
risk
infecti
complic
howev
still
mani
pathogen
vaccin
effect
prevent
strategi
chapter
discuss
common
infect
encount
transplant
set
howev
exhaust
review
infecti
diseas
beyond
scope
chapter
excel
resourc
contain
comprehens
guidelin
major
infecti
diseas
encount
clini
cytomegaloviru
import
viral
infect
develop
solid
organ
transplant
associ
signifi
cant
morbid
mortal
cmv
member
betaherpesviru
famili
seropreval
gener
adult
popul
rang
age
viru
establish
lifelong
latenc
host
primari
infect
cmv
immunocompet
host
may
asymptomat
may
manifest
fever
malais
mononucleosistyp
syndrom
primari
infect
viru
typic
remain
latent
system
sign
symptom
reactiv
howev
transplant
recipi
effect
cmv
myriad
includ
viral
syndrom
fever
leukopenia
thrombocytopenia
may
compound
immunosuppress
medic
also
tissueinvas
diseas
potenti
involv
transplant
organ
well
lung
liver
gastrointestin
tract
rare
retina
cmv
also
associ
sever
indirect
effect
solid
organ
tranplant
patient
includ
increas
risk
reject
reduc
longterm
surviv
increas
risk
opportunist
infect
bacteri
infect
allograft
dysfunct
prior
widespread
use
antivir
prophylaxi
cmv
diseas
occur
fi
rst
month
solid
organ
transplant
donorseropositiverecipientseroneg
patient
highest
risk
diseas
addit
donor
seroposit
major
risk
factor
cmv
infect
diseas
includ
degre
immunosuppress
includ
use
antilymphocyt
monoclon
antibodi
therapi
induct
treatment
reject
reject
concurr
viral
infect
eg
human
herpesviru
infect
primari
cmv
infect
via
transplant
organ
seroneg
recipi
reactiv
latent
diseas
seroposit
recipi
superinfect
donor
viru
seroposit
recipi
caus
symptomat
diseas
two
strategi
use
cmv
prevent
atrisk
patient
univers
prophylaxi
preemptiv
therapi
univers
cmv
prophylaxi
involv
give
antivir
therapi
atrisk
patient
ie
either
cmvseroposit
donor
recipi
time
transplant
immedi
afterward
specifi
ed
period
goal
prevent
cmv
diseas
period
maximum
immunosuppress
approach
may
prefer
patient
close
monitor
cmv
diseas
possibl
practic
although
numer
approach
includ
acyclovir
valacyclovir
cmv
immunoglobulin
associ
reduct
cmv
diseas
ganciclovir
mainstay
cmv
treatment
prophylaxi
solid
organ
transplant
recipi
studi
show
improv
effi
caci
acyclovir
popul
intraven
form
ganciclovir
given
way
oral
formul
mani
center
due
eas
administr
oral
ganciclovir
signifi
cantli
lower
bioavail
intraven
form
dose
gram
three
time
day
proven
effi
caci
reduc
incid
cmv
diseas
valin
ester
prodrug
ganciclovir
valganciclovir
improv
bioavail
compar
oral
ganciclovir
dose
mg
daili
shown
equal
effi
caciou
renal
transplant
patient
slightli
increas
incid
neutropenia
compar
ganciclovir
vs
valganciclovir
indic
patient
undergo
combin
liver
kidney
transplant
due
report
breakthrough
cmv
diseas
liver
transplant
recipi
receiv
valganciclovir
prophylaxi
preemptiv
therapi
requir
close
monitor
patient
sign
cmv
reactiv
primari
infect
prompt
initi
anticmv
therapi
prevent
progress
cmv
diseas
blood
cmv
dna
rna
level
cmv
antigenemia
assay
util
weekli
interv
initi
posttransplant
phase
longer
interv
immunosuppress
reduc
cultur
techniqu
includ
shell
vial
fallen
favor
due
long
turnaround
time
poor
sensit
random
trial
prophylact
preemptiv
oral
valganciclovir
publish
compar
prophyloct
valganciclavir
mg
daili
day
posttranspl
preemptiv
valganciclovir
mg
twice
day
day
trial
measur
whether
cmv
dna
level
rose
copiesml
blood
sampl
assess
weekli
fi
rst
week
month
posttranspl
signifi
cant
differ
effi
caci
prevent
cmv
diseas
costsensit
analysi
similar
approach
optim
durat
cmv
prophylaxi
remain
unclear
mani
center
use
prophylaxi
fi
rst
month
transplant
cmv
diseas
typic
occur
later
transplant
often
median
month
posttranspl
donorseropositiverecipientseroneg
patient
unfortun
extens
prophylaxi
beyond
month
rais
concern
drug
toxic
develop
drug
resist
although
studi
highrisk
solid
organ
transplant
patient
receiv
day
valganciclovir
prophylaxi
fail
show
develop
drug
resist
monitor
immun
marker
cmv
also
appear
predict
develop
cmv
diseas
recent
studi
larosa
colleagu
suggest
studi
examin
interferon
gamma
releas
cell
biweekli
interv
month
transplant
associ
found
presenc
absenc
tcell
respons
develop
cmv
diseas
howev
failur
develop
igg
antibodi
month
posttranspl
patient
seroneg
time
transplant
may
predict
lateonset
cmv
diseas
develop
diseas
vs
patient
cmv
igg
month
standard
treatment
cmv
diseas
use
intraven
ganciclovir
mgkg
twice
daili
dose
adjust
renal
insuffi
cienci
reduct
immunosuppress
resolut
symptom
cmv
viremia
unfortun
ganciclovirresist
cmv
emerg
uncommon
grow
problem
solid
organ
transplant
popul
perhap
due
prolong
use
oral
ganciclovir
prophylaxi
potent
immunosuppress
regimen
although
commonli
report
recipi
kidney
transplant
alon
may
occur
frequent
pancrea
transplant
recipi
major
risk
factor
prolong
exposur
lowdos
ganciclovir
period
asymptomat
infect
resist
detect
via
phenotyp
genotyp
test
usual
requir
addit
time
failur
respond
adequ
dose
ganciclovir
rais
suspicion
ganciclovir
resist
substitut
anoth
antivir
agent
may
warrant
option
treatment
resist
cmv
includ
foscarnet
without
ganciclovir
cidofovir
may
highli
nephrotox
especi
use
context
calcineurin
inhibitor
adjunct
intraven
immunoglobulin
cmv
specifi
c
nonspecifi
c
use
treatment
refractori
cmv
diseas
although
largescal
trial
specifi
c
guidelin
use
similar
cmv
ebv
ubiquit
herpesviru
also
establish
latent
infect
host
ebv
member
gammaherpesviru
famili
along
human
herpesviru
kaposi
sarcomaassoci
herpesviru
kshv
ebv
infect
immunocompet
host
may
asymptomat
acquir
childhood
may
result
infecti
mononucleosi
young
adult
popul
seroposit
adulthood
transplant
recipi
ebv
associ
ptld
group
disord
involv
vari
degre
abnorm
bcell
tcell
prolifer
patient
highest
risk
ptld
seroneg
recipi
acquir
primari
infect
transplant
make
pediatr
patient
especi
vulner
viru
effi
cientli
transmit
via
saliva
bodi
fl
uid
may
also
transmit
lymphocyt
transplant
allograft
risk
ptld
vari
organ
transplant
smallbowel
transplant
recipi
highest
risk
lung
heart
pancrea
liver
patient
moder
risk
renal
transplant
recipi
lowest
risk
approxim
risk
factor
includ
type
durat
immunosuppress
includ
polyclon
antibodi
use
recent
analysi
french
registri
ptld
renal
transplant
recipi
demonstr
incid
year
surviv
rate
year
diagnosi
infect
hepat
b
c
also
note
risk
factor
patient
death
addit
commonli
recogn
risk
factor
diagnosi
ptld
initi
requir
clinic
suspicion
present
may
variabl
rang
infecti
mononucleosislik
syndrom
local
diffus
lymphat
tissu
involv
even
isol
allograft
involv
standard
test
diagnosi
biopsi
involv
site
examin
cellular
phenotyp
clonal
well
examin
presenc
ebv
gene
product
eber
via
situ
hybrid
stage
perform
special
attent
paid
allograft
involv
presenc
multifoc
diseas
includ
involv
central
nervou
system
categori
ptld
ie
monomorph
vs
polymorph
b
cell
vs
cell
ebv
viral
load
test
yet
establish
accept
diagnost
test
ptld
viremia
variabl
correl
specifi
calli
presenc
absenc
ptld
low
viral
load
good
neg
predict
valu
high
viral
load
nonspecifi
c
certain
subtyp
ptld
ebvneg
studi
current
underway
examin
differ
ebv
antigen
marker
patient
risk
develop
ptld
possibl
also
surrog
marker
global
immunosuppress
level
prevent
strategi
ptld
limit
systemat
studi
variou
modal
lack
identifi
cation
highrisk
recipi
recommend
specifi
calli
ebvseroneg
recipi
risk
cmv
diseas
avoid
overzeal
immunosuppress
encourag
well
shown
risk
factor
develop
ptld
benefi
antivir
prophylaxi
specifi
calli
target
toward
ebv
establish
cmv
prophylaxi
regimen
may
benefi
reduc
risk
ptld
use
prophylact
cmv
intraven
immunoglobulin
ivig
prove
effi
caciou
small
clinic
trial
treatment
earli
ptld
begin
reduct
immunosuppress
may
result
spontan
regress
case
renal
transplant
patient
confi
rmed
ptld
prompt
cessat
immunosuppress
even
expens
reject
allograft
retransplant
recoveri
ptld
possibl
recent
optn
uno
databas
studi
show
retransplant
patient
surviv
graft
surviv
mean
followup
day
treatment
modal
includ
surgic
debulk
tumor
explant
allograft
involv
referr
oncologist
monoclon
bcell
antibodi
therapi
rituximab
tumor
cell
cytotox
chemotherapi
refractori
diseas
varieti
treatment
modal
investig
includ
interferon
alfa
adopt
immunotherapi
use
patient
lymphocyt
activ
ex
vivo
lateonset
ebvneg
ptld
typic
respond
well
reduct
immunosuppress
thu
requir
aggress
therapeut
measur
earli
consult
oncologist
prudent
patient
herp
simplex
vzv
member
alphaherpesviru
famili
like
herpesvirus
establish
lifelong
latenc
primari
infect
seropreval
common
etiolog
agent
orolabi
lesion
unit
state
wherea
seropreval
genit
ulcer
diseas
exce
antibodi
vzv
caus
chickenpox
zostershingl
present
adult
although
epidemiolog
viru
may
chang
futur
due
adopt
univers
vaccin
children
unit
state
diseas
caus
virus
secondari
reactiv
latent
infect
howev
seroneg
patient
primari
infect
may
acquir
rare
via
transmiss
allograft
commonli
commun
spread
usual
earli
posttranspl
cours
prophylaxi
given
reactiv
may
present
local
orolabi
genit
ulcer
dissemin
diseas
may
occur
caus
pneumon
hepat
similarli
vzv
may
reactiv
dermatom
zoster
also
caus
gener
skin
diseas
well
invas
diseas
involv
lung
gastrointestin
tract
central
nervou
system
center
use
oral
acyclovir
mg
oral
bid
tid
valacylovir
mg
daili
prophylaxi
vzv
patient
receiv
prophylaxi
cmv
regimen
cmv
prophylaxi
use
ganciclovir
valganciclovir
also
effect
vzv
serostatu
prospect
transplant
recipi
assess
earli
evalu
process
live
attenu
varicella
vaccin
administ
well
transplant
occur
previous
infect
immunocompet
host
varicella
vaccin
shown
reduc
incid
zoster
whether
varicella
vaccin
safe
effect
prevent
zoster
transplant
unknown
betaherpesvirus
identifi
ed
respect
tend
caus
primari
infect
childhood
roseola
infantum
exanthema
subitum
nonspecifi
c
febril
ill
establish
latenc
adult
adult
demonstr
seroposit
virus
role
reactiv
virus
posttransplant
period
still
investig
appear
may
immunomodulatori
effect
either
independ
combin
especi
reactiv
often
found
context
cmv
diseas
primari
diseas
caus
report
includ
bone
marrow
suppress
enceph
hepat
coliti
pneumon
fatal
hemophagocyt
syndrom
wherea
primari
syndrom
less
welldescrib
prospect
studi
betaherpesviru
viremia
renal
transplant
cmv
commonli
detect
viru
occur
patient
occur
earliest
patient
occur
patient
interestingli
author
found
correl
viremia
increas
number
reject
episod
analysi
restrict
patient
reject
overal
associ
presenc
betaherpesviru
viremia
occurr
reject
increas
incid
cmv
diseas
patient
demonstr
infect
cmv
detect
accomplish
nucleic
acid
test
prevent
strategi
remain
undefi
ned
ganciclovir
may
effect
prophylaxi
variabl
suscept
agent
may
exist
b
variant
viru
appear
affect
ganciclovir
prophylaxi
virus
appear
resist
acyclovir
optim
treatment
virus
cloud
frequent
coinfect
cmv
ganciclovir
foscarnet
cidofovir
appear
reduc
viremia
use
coincid
cmv
diseas
unclear
reduct
due
clearanc
cmv
resolut
immunomodulatori
effect
direct
antivir
effect
individu
case
report
reduct
immunosuppress
ganciclovir
treatment
infect
publish
human
herpesviru
gammaherpesviru
relat
ebv
similarli
establish
latenc
primari
infect
caus
kaposi
sarcoma
ks
primari
effus
lymphoma
form
multicentr
castleman
diseas
seroposit
geograph
restrict
herpesvirus
highest
preval
rate
africa
middl
east
unit
state
seropreval
estim
less
although
certain
popul
ie
men
sex
men
rate
may
higher
seroconvers
posttranspl
appear
depend
donor
statu
perhap
geograph
locat
recipi
although
studi
solid
organ
transplant
recipi
pittsburgh
show
seroposit
rose
transplant
presum
donorneg
organ
document
neg
via
serum
sampl
regardless
patient
age
type
organ
receiv
incid
ks
estim
time
higher
solid
organ
transplant
recipi
compar
gener
popul
rate
unit
state
report
us
patient
present
cutan
ks
diseas
occur
median
month
transplant
detect
antibodi
use
establish
seroconvers
assay
detect
serum
nucleic
acid
avail
detect
viremia
guidelin
exist
prevent
diseas
although
replic
viru
appear
suscept
vitro
ganciclovir
foscarnet
cidofovir
treatment
posttransplant
ks
depend
extent
diseas
ie
cutan
viscer
involv
typic
begin
reduct
immunosuppress
necessari
radiotherapi
chemotherapi
may
ad
extens
diseas
recent
seri
renal
transplant
recipi
posttransplant
ks
success
treat
discontinu
cyclosporin
mycophenol
mofetil
addit
sirolimu
sirolimu
immunosuppress
medic
target
mtor
prevent
prolifer
cell
inhibit
growth
sever
tumor
cell
line
vitro
inhibit
akt
protein
kinas
mtor
signal
pathway
implic
ks
pathogenesi
sirolimu
trough
level
maintain
ngml
episod
reject
occur
patient
respiratori
virus
adenoviru
respiratori
syncyti
viru
infl
uenza
parainfl
uenza
hospit
primari
mean
prevent
virus
along
yearli
infl
uenza
vaccin
transplant
recipi
household
contact
healthcar
worker
adenoviru
caus
symptomat
invas
diseas
ie
hemorrhag
cystiti
gastroenter
pneumon
occasion
fatal
transplant
recipi
commonli
pediatr
patient
vaccin
prophylaxi
current
avail
adenoviru
defi
nitiv
treatment
recommend
establish
sever
case
report
suggest
cidofovir
may
effi
caciou
treat
hematopoet
stem
cell
transplant
patient
although
dose
recommend
unclear
dose
cidofovir
mgkg
everi
week
may
caus
nephrotox
dose
mgkg
three
time
per
week
may
caus
breakthrough
cmv
hsv
infect
ribavirin
also
use
treatment
tissueinvas
adenovir
diseas
antivir
activ
limit
certain
serotyp
adenoviru
signifi
cant
toxic
associ
use
convinc
effi
caci
data
shown
warrant
recommend
use
ganciclovir
vitro
activ
adenoviru
defi
nitiv
data
support
use
treatment
adenovir
diseas
confl
ict
data
exist
regard
prophylact
benefi
ts
insuffi
cient
evid
exist
use
agent
zalcitabin
vidarabin
treatment
reduct
immunosuppress
attempt
case
along
support
care
rsv
common
pediatr
pathogen
caus
season
diseas
winter
month
usual
among
children
age
younger
appear
immun
viru
lifelong
transplant
recipi
may
manifest
sever
diseas
immunocompet
host
manifest
typic
pulmonari
develop
lower
respiratori
tract
diseas
portend
wors
prognosi
benefi
prophylaxi
palivizumab
rsvivig
adult
transplant
recipi
proven
data
limit
treatment
establish
rsv
diseas
solid
organ
transplant
patient
benefi
may
exist
use
aerosol
ribavirin
combin
palivizumab
rsvivig
earli
lower
tract
diseas
mainstay
prevent
infl
uenza
b
yearli
vaccin
transplant
recipi
close
contact
prefer
vaccin
combin
inactiv
antigen
strain
infl
uenza
b
predict
via
epidemiolog
studi
circul
given
year
thu
composit
may
chang
yearli
basi
although
respons
transplant
patient
lower
healthi
immunocompet
individu
suffi
cient
level
protect
like
occur
individu
earli
concern
increas
risk
graft
reject
result
immun
respons
vaccin
support
literatur
recent
multicent
retrospect
analysi
reject
heart
transplant
recipi
found
associ
infl
uenza
vaccin
episod
reject
infect
suspect
rapid
treatment
initi
within
hour
symptom
develop
concurr
diagnost
test
nucleic
acid
detect
neuraminidas
inhibitor
oseltamivir
zanamivir
becom
mainstay
therapi
effi
caciou
b
strain
infl
uenza
howev
studi
specifi
calli
evalu
effi
caci
transplant
recipi
yet
conduct
treatment
dose
oseltamivir
mg
oral
twice
day
day
zanamivir
avail
inhal
agent
prophylaxi
oseltamivir
may
also
benefi
cial
within
hour
case
known
suspect
exposur
infl
uenza
dose
mg
oral
day
minimum
day
use
amantidin
rimantidin
fallen
favor
due
lack
effi
caci
infl
uenza
b
recent
report
resist
infl
uenza
infl
uenza
season
parainfl
uenza
virus
tend
circul
fall
winter
month
typic
produc
nonspecifi
c
upper
respiratori
tract
symptom
current
vaccin
prophylaxi
accept
treatment
regimen
virus
incid
new
acquisit
hepat
b
hemodialysi
period
markedli
reduc
sinc
adopt
improv
infect
control
practic
widespread
use
hepat
b
vaccin
adopt
reduc
incid
hepat
b
acquisit
vaccin
patient
compens
renal
diseas
well
advanc
dialysi
depend
encourag
use
fourdos
vaccin
schedul
month
yearli
monitor
hbsab
titer
conduct
booster
vaccin
given
need
current
preval
among
hemodialysi
patient
approxim
among
dialysi
patient
seroconvert
may
develop
chronic
hepat
b
subset
patient
undergo
transplant
becom
hbsagneg
reactiv
transplant
patient
receiv
transplant
hbsagposit
poorer
prognosi
high
rate
chronic
hepat
year
also
increas
likelihood
sepsi
hepatocellular
carcinoma
posttranspl
period
high
risk
hbv
transmiss
exist
graft
hbsagposit
organ
seroneg
recipi
circumst
avoid
transplant
hepat
bsagnegativecabposit
kidney
may
undertaken
seroneg
recipi
recipi
fulli
vaccin
donor
hbv
dnaneg
although
recipi
may
seroconvert
base
presenc
new
hbcab
affect
patient
surviv
graft
function
close
followup
recipi
monitor
transmiss
hepat
b
import
use
hepat
b
immunoglobulin
pharmacotherapi
may
warrant
situat
recipi
hepat
b
close
monitor
viral
load
hbeag
warrant
liver
biopsi
transplant
assess
extent
hepat
cirrhosi
perform
extens
liver
diseas
present
transplant
higher
liverassoci
mortal
transplant
treatment
patient
may
includ
use
nucleosid
analog
lamivudin
adefovir
entecavir
telbivudin
nucleotid
analog
tenofovir
treatment
lamivudin
typic
result
larg
reduct
hbv
dna
resist
may
develop
prolong
use
drug
year
approach
advoc
transplant
suppress
viral
load
continu
transplant
nonhepat
recipi
chronic
hepat
b
tenofovir
adefovir
associ
nephrotox
patient
transplant
recipi
rais
concern
safeti
renal
transplant
recipi
recent
data
regard
use
longterm
year
adefovir
chronic
hepat
b
patient
recent
publish
suggest
agent
well
toler
small
risk
renal
insuffi
cienci
year
low
risk
develop
resist
year
smaller
analysi
renal
transplant
recipi
chronic
hepat
b
resist
lamivudin
report
show
signifi
cant
reduct
hepat
b
dna
evid
adefovirrel
renal
toxic
median
month
treatment
although
sever
patient
requir
phosphoru
supplement
pretranspl
treatment
interferonalfa
reduc
viral
load
promot
seroconvers
investig
renal
transplant
recipi
specifi
c
guidelin
regard
use
publish
approach
current
recommend
infect
hepat
c
lead
chronic
infect
expos
individu
cirrhosi
develop
approxim
year
individu
fortun
rate
hcv
infect
hemodialysi
popul
declin
due
improv
infect
control
measur
screen
blood
product
howev
de
novo
infect
still
occur
dialysi
set
seroconvers
rate
per
personyear
recent
preval
studi
screen
potenti
renal
transplant
recipi
donor
critic
discoveri
chronic
infect
hcv
implic
treatment
surveil
hepat
c
effi
cientli
transfer
via
transplant
organ
seroconvers
occur
recipi
hcvposit
organ
detect
hcv
rna
recipi
result
underscor
difficulti
reli
sole
serolog
test
transplant
recipi
nucleic
acid
test
hcv
requir
immunocompromis
host
includ
dialysi
patient
transplant
recipi
transmiss
viru
occur
frequent
hcvseroposit
donor
consid
extendedcriteria
donor
typic
reserv
hcvposit
recipi
special
circumst
nucleic
acid
test
hepat
c
rna
antibodyposit
renal
donor
help
identifi
donor
virem
therefor
like
transmit
hepat
c
effect
hcv
posit
graft
patient
surviv
variabl
cohort
patient
renal
transplant
wait
list
hcvposit
patient
higher
risk
death
compar
hcvneg
patient
regardless
whether
remain
dialysi
underw
transplant
howev
hcvposit
recipi
underw
transplant
seroneg
recipi
receiv
hcvposit
kidney
improv
longterm
surviv
compar
patient
remain
dialysi
month
hcv
infect
posttranspl
period
associ
increas
chanc
newonset
diabet
mellitu
sepsi
hcvrelat
glomerulonephropathi
longterm
mortal
graft
failur
recent
studi
suggest
hepat
c
infect
renal
transplant
patient
may
necessarili
predispos
recipi
rapid
progress
liver
diseas
increas
variabl
hypervari
region
hcv
e
glycoprotein
may
predictor
lack
progress
fi
brosi
implic
chronic
hepat
c
infect
posttranspl
period
effort
made
stage
extent
diseas
transplant
candid
serum
transaminas
refl
ect
extent
liver
fi
brosi
cirrhosi
liver
biopsi
perform
transplant
evalu
determin
extent
liver
damag
treatment
hepat
c
pretranspl
period
also
consid
effort
erad
viru
ribavirin
peginterferonalfa
combin
treatment
choic
advers
effect
anemia
prevent
use
ribavirin
popul
transplant
interferonalfa
associ
increas
risk
renal
failur
possibl
graft
reject
gener
recommend
use
renal
transplant
bk
viru
doublestrand
dna
polyoma
viru
infect
adult
popul
appear
primarili
asymptomat
immunocompet
host
although
upper
respiratori
symptom
cystiti
report
renal
transplant
recipi
bk
viru
transmit
transplant
organ
reactiv
latenc
seroposit
recipi
typic
viru
caus
asymptomat
viruria
popul
patient
nephropathi
allograft
dysfunct
ureter
stenosi
strictur
develop
result
bk
diseas
risk
factor
develop
bk
viremia
viruria
unclear
extent
immunosuppress
appear
critic
antireject
treatment
method
screen
interv
use
diagnosi
bk
viru
infect
welldefi
ned
includ
frequent
urin
cytolog
examin
look
abnorm
epitheli
decoy
cell
sensit
pcr
method
detect
urin
blood
specimen
nucleic
acid
techniqu
also
provid
quantit
assess
viral
load
abl
differenti
bk
viru
infect
virus
may
produc
similar
cytolog
appear
epitheli
cell
ie
jc
viru
plasma
viral
load
greater
copiesml
urin
viral
load
greater
copiesml
suggest
underli
bk
viru
nephropathi
bkvn
diagnosi
stage
bkvn
requir
renal
biopsi
incid
bkvn
appear
rang
renal
transplant
recipi
recent
research
examin
util
nucleic
acidbas
detect
techniqu
screen
tool
develop
bk
viruria
viremia
nephropathi
level
bk
viremia
presenc
recurr
viremia
correl
presenc
bkvn
treatment
prevent
bk
viru
still
evolv
reduct
immunosuppress
remain
mainstay
prevent
therapi
bk
viruria
viremia
nephropathi
antivir
agent
uniformli
effi
caciou
prevent
treatment
bk
viruria
sever
anecdot
report
includ
cidofovir
lefl
unomid
unfortun
random
control
clinic
trial
perform
either
agent
use
may
warrant
patient
sever
bkvn
concurr
reject
may
limit
reduct
immunosuppres
cidofovir
activ
polyoma
virus
vitro
nephrotox
led
reduc
dose
renal
transplant
patient
treatment
bk
viru
infect
mgkg
given
intraven
everi
week
clinic
result
remain
mix
patient
bkvn
treat
cidofovir
univers
pittsburgh
viremia
clear
patient
lost
graft
compar
histor
graft
loss
rate
without
cidofovir
lefl
unomid
drug
use
treatment
rheumatoid
arthriti
also
antivir
activ
bk
viru
vitro
limit
amount
data
avail
regard
clinic
util
seri
patient
biopsyproven
bkvn
treat
lefl
unomid
load
dose
mgday
day
mg
per
day
titrat
maintain
blood
level
higher
gml
patient
achiev
blood
level
greater
gml
reduct
clearanc
viru
urin
blood
month
persist
respons
beyond
time
howev
pharmacokinet
lefl
unomid
unpredict
make
uniform
dose
recommend
diffi
cult
serum
drug
level
monitor
necessari
quinolon
ivig
also
explor
treatment
bk
viru
infect
limit
clinic
data
avail
effi
caci
recommend
made
agent
studi
perform
retransplant
bkvn
feasibl
low
risk
recurr
bkvn
regardless
transplant
nephrectomi
retransplant
presenc
activ
bkvn
viremia
morbid
mortal
fungal
infect
transplant
recipi
remain
high
despit
recent
advanc
antifung
medic
diagnost
test
compar
transplant
recipi
renal
transplant
patient
lower
risk
fungal
infect
unless
receiv
simultan
pancrea
transplant
despit
reduc
risk
clinician
need
remain
vigil
unexplain
fever
respiratori
symptom
skin
lesion
possibl
manifest
fungal
diseas
unpredict
clinic
sign
symptom
fungal
infect
diffi
culti
interpret
radiolog
studi
biopsi
limit
number
laboratorybas
marker
fungal
infect
often
result
dissemin
invas
fungal
diseas
proper
treatment
initi
ad
diffi
culti
manag
interact
immunosuppress
medic
mani
antifung
medic
increas
complex
treat
infect
fungal
infect
earli
transplant
period
month
typic
involv
candida
speci
rare
instanc
nosocomi
transmiss
environment
fungal
pathogen
cryptococcu
neoforman
aspergillu
speci
varieti
risk
factor
associ
earli
invas
fungal
infect
transplant
includ
simultan
pancrea
transplant
pancrea
transplant
kidney
transplant
enter
bladder
drainag
procedur
primari
allograft
dysfunct
prolong
transplant
surgeri
high
intraop
blood
loss
prolong
intens
care
unit
stay
chronic
graft
dysfunctionreject
presenc
immunomodul
virus
prolong
use
antibiot
artifi
cial
stent
donor
fungemia
prior
concurr
fungal
infect
recipi
care
must
taken
identifi
speci
candida
isol
therapeut
reason
candida
albican
remain
suscept
fl
uconazol
candida
speci
becom
frequent
pathogen
uniformli
suscept
fl
uconazol
ie
candida
glabrata
may
resist
dosedepend
suscept
candida
kruseii
intrins
resist
choic
empir
therapi
lifethreaten
candid
infect
depend
epidemiolog
isol
individu
institut
may
includ
highdos
fl
uconazol
voriconazol
echinocandin
later
posttranspl
period
patient
risk
environment
pathogen
endem
mycos
via
primari
exposur
reactiv
latent
diseas
aspergillu
cryptococcu
neoforman
infect
commonli
encount
fungal
pathogen
period
risk
factor
fungal
infect
includ
diabet
prolong
pretranspl
dialysi
use
tacrolimu
treatment
reject
care
histori
includ
travel
workplac
home
exposur
ie
construct
remodel
pet
hobbi
garden
spelunk
elicit
care
review
system
perform
radiolog
studi
may
warrant
suspici
skin
lesion
biopsi
suggest
diagnost
test
treatment
regimen
candida
aspergillu
cryptococcu
summar
tabl
pneumocysti
jiroveci
formerli
pneumocysti
carinii
remain
import
caus
respiratori
diseas
transplant
recipi
despit
excel
prophylaxi
regimen
use
potent
immunosuppress
ultim
cessat
prophylaxi
approxim
month
posttranspl
requir
physician
consid
pneumocysti
infect
transplant
recipi
fl
ulik
symptom
persist
respiratori
complaint
includ
dri
cough
dyspnea
radiograph
fi
nding
may
atyp
transplant
recipi
manifest
diffus
groundglass
infi
ltrate
focal
consolid
pneumothorax
prophylaxi
trimethoprimsulfamethoxazol
fi
rst
month
transplant
strongli
recommend
also
reduc
risk
opportunist
infect
toxoplasmosi
listeriosi
nocardiosi
well
bacteri
urinari
tract
infect
uti
patient
toler
trimethoprimsulfamethoxazol
agent
use
aerosol
pentamidin
atovaquon
dapson
care
must
taken
monitor
complianc
advers
effect
medic
treatment
pneumocysti
diseas
trimethoprimsulfamethoxazol
mgkg
daili
four
divid
dose
corticosteroid
given
hypoxia
po
lower
mm
hg
arteri
blood
ga
document
minimum
cours
trimethoprimsulfamethoxazol
often
suffi
cient
immunosuppress
reduc
mg
prednison
day
follow
taper
recommend
concomit
hypoxemia
urinari
tract
infect
especi
involv
transplant
kidney
commonli
encount
bacteri
infect
renal
transplant
recipi
incid
uti
popul
estim
infect
common
sourc
gramneg
bacteremia
high
rate
infect
like
due
sever
factor
includ
surgic
factor
eg
refl
uxe
vs
nonrefl
uxe
anastomosi
uret
ureter
stent
placement
impair
bladder
empti
presenc
durat
bladder
cathet
immunosuppress
increas
concern
number
highli
resist
gramneg
organ
isol
patient
limit
number
antimicrobi
option
treatment
impact
earli
uti
renal
transplant
recipi
associ
pyelonephr
bacteremiasepticemia
increas
mortal
compar
gener
popul
late
uti
may
also
associ
increas
mortal
although
tend
mimic
uti
immunocompet
host
center
provid
prophylaxi
earli
uti
use
either
trimethoprimsulfamethoxazol
quinolon
fi
rst
month
transplant
use
trimethoprimsulfamethoxazol
inexpens
also
provid
prophylaxi
pneumocysti
toxoplasmosi
listeriosi
nocardiosi
although
quinolon
may
better
toler
center
use
lowdos
trimethoprimsulfamethoxazol
daili
studi
suggest
higher
dose
mg
may
effi
caciou
prevent
uti
fi
rst
month
transplant
whether
higher
dose
may
associ
increas
toxic
unknown
treatment
uti
popul
requir
close
attent
paid
suscept
isol
rate
highli
resist
gramneg
pathogen
appear
increas
center
use
longer
durat
treatment
transplant
recipi
typic
day
candid
uti
popul
also
problemat
may
lead
format
fungal
ball
result
urinari
obstruct
fi
nding
yeast
steril
urin
specimen
prompt
investig
although
tuberculosi
tb
remain
rel
rare
diseas
renal
transplant
complex
treatment
high
associ
mortal
requir
vigil
provid
pretranspl
posttranspl
period
incid
tb
renal
transplant
unit
state
estim
less
mortal
rate
patient
approach
patient
develop
symptomat
diseas
within
fi
rst
year
transplant
evalu
transplant
recipi
includ
detail
histori
prior
tb
possibl
exposur
diseas
travel
endem
area
tuberculin
skin
test
recommend
potenti
recipi
interpret
posit
greater
mm
indur
detect
prior
prophylaxi
given
patient
respons
test
recent
convert
posit
patient
treat
latent
tb
infect
unfortun
mani
patient
sever
renal
diseas
may
anerg
render
test
unreli
neg
recent
releas
blood
test
interferongamma
releas
patient
sensit
lymphocyt
exposur
purifi
ed
protein
deriv
quantiferon
test
promis
yet
indic
use
immunosuppress
individu
chest
radiograph
may
use
fi
nding
evid
prior
activ
diseas
would
warrant
evalu
especi
prior
treatment
prophylaxi
given
patient
latent
tb
infect
suggest
treatment
mg
isoniazid
daili
month
recommend
evalu
underli
liver
diseas
ideal
prophylaxi
complet
transplant
onset
sever
immunosuppress
howev
donor
risk
factor
latent
tb
infect
recipi
receiv
prophylaxi
transplant
reduc
risk
transmiss
diseas
liver
function
test
monitor
everi
week
fi
rst
week
therapi
monthli
look
elev
transaminas
greater
time
normal
diagnosi
treatment
activ
tuberculosi
transplant
complex
involv
infecti
diseas
specialist
recommend
well
involv
local
public
health
depart
patient
like
present
fi
rst
year
transplant
like
present
dissemin
diseas
immunocompet
patient
although
pulmonari
diseas
remain
common
manifest
diagnosi
may
requir
extens
imag
multipl
specimen
suspici
area
microbiolog
cultur
suscept
test
use
quantiferon
test
valid
diagnosi
activ
infect
immunosuppress
patient
standard
fourdrug
regimen
typic
initi
diagnosi
tb
isoniazid
rifampin
pyrazinamid
ethambutol
problemat
transplant
recipi
due
interact
rifampin
calcineurin
inhibitor
induc
metabol
agent
substitut
rifabutin
quinolon
levofl
oxacin
common
approach
elimin
problem
although
rifabutin
still
associ
signifi
cant
drug
interact
suscept
isol
isoniazid
rifampin
confi
rmed
therapi
continu
minimum
month
isoniazid
rifampin
rifabutin
use
longer
regimen
sever
diseas
nontubercul
mycobacteri
infect
transplant
recipi
rare
wellstudi
mani
organ
environment
contamin
caus
diseas
result
nosocomi
transmiss
exposur
commun
high
index
suspicion
must
maintain
earli
involv
infecti
diseas
specialist
help
mani
organ
requir
special
growth
condit
microbiolog
laboratori
uniform
suscept
antimicrobi
agent
detail
recommend
found
recent
publish
guidelin
widespread
use
highli
activ
antiretrovir
therapi
haart
chang
prognosi
patient
human
immunodefi
cienci
viru
hiv
infect
allow
patient
consid
renal
transplant
prior
widespread
use
haart
retrospect
analysi
hivposit
renal
transplant
recipi
suggest
slightli
wors
surviv
compar
hivneg
patient
period
vs
recent
sever
case
seri
report
encourag
result
renal
transplant
hivposit
patient
show
similar
graft
surviv
mortal
year
compar
control
uno
databas
unfortun
graft
reject
rate
appear
higher
hivposit
group
current
prospect
multicent
trial
underway
studi
hivposit
renal
liver
transplant
recipi
studi
effect
immunosuppress
medic
patient
surviv
hiv
infect
haart
affect
graft
surviv
ideal
hivposit
patient
consid
transplant
cell
count
greater
cellsl
undetect
viral
load
month
stabl
antiretrovir
therapi
comorbid
condit
assess
includ
presenc
viral
infect
ie
hbv
hcv
may
acceler
cours
presenc
hiv
immunosuppress
histori
opportunist
infect
may
reactiv
posttransplant
transplant
patient
requir
close
monitor
pharmacokinet
drug
interact
antiretrovir
medic
immunosuppress
medic
may
complex
notabl
signifi
cant
drug
interact
calcineurin
inhibitor
antiretrovir
agent
includ
proteas
inhibitor
nonnucleosid
revers
transcriptas
inhibitor
frequent
assess
serum
drug
level
calcineurin
inhibitor
therefor
mandatori
patient
proteas
inhibitorbas
haart
comprehens
guidelin
establish
cooper
clinic
trial
adult
transplant
group
includ
specifi
c
recommend
regard
inclus
exclus
criteria
pharmacolog
consider
haart
immunosuppress
prophylaxi
regimen
manag
infecti
diseas
complic
continu
pose
challeng
physician
treat
transplant
recipi
use
newer
potent
immunosuppress
regimen
becom
common
risk
opportunist
pathogen
sever
manifest
communityacquir
nosocomi
pathogen
increas
continu
attent
improv
prevent
diagnost
treatment
strategi
minim
impact
infect
outcom
requir
